# US 2021/0330637 A1 · Cannabichromene formulation for pain management

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330637 A1
- Document ID: US20210330637A1
- Status: Published application
- Kind: A1
- Application number: 17/038,048
- Filed: 2020-09-30
- Published: 2021-10-28
- Earliest claimed: 2020-04-24
- Assignees: Zyus Life Sciences Inc.
- Applicants: Zyus Life Sciences Inc.
- Inventors: Mahsa ABRISHAMI
- Web page: https://patentgrep.com/patent/US20210330637A1

## CPC

- A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol}
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A formulation for pain management is provided comprising cannabichromene as the primary cannabinoid together with an excipient and, optionally, one or more secondary cannabinoids in an amount of up to 5% by weight of the primary cannabinoid. The formulation is essentially free of tetrahydrocannabinol. The types of pain to be managed with the formulation include but are not limited to the treatment of neuropathic pain, pain due to cancer, injury, accident, surgery, or tissue damage. Methods of use of the formulation, doses and dosage forms are described.

## Claims

### Claim 1

A formulation for use in pain management by a subject in need thereof, said formulation comprising a primary cannabinoid and one or more excipient, diluent, or carrier;
wherein said primary cannabinoid consists of cannabichromene (CBC), and wherein said formulation is essentially free of tetrahydrocannabinol (THC).

### Claim 2 (depends on 1)

The formulation for use in pain management according to claim 1, wherein the pain management comprises treatment of pain due to neuropathic pain, cancer, chemotherapy, inflammation, diabetes, diabetic neuropathy, post-shingles neuralgia, peripheral neuropathy, multiple sclerosis, injury, accident, surgery, or tissue damage.

### Claim 3 (depends on 1)

The formulation for use in pain management according to claim 1, additionally comprising one or more secondary cannabinoids.

### Claim 4 (depends on 3)

The formulation for use in pain management according to claim 3, wherein the one or more secondary cannabinoids comprises cannabidiol (CBD).

### Claim 5 (depends on 3)

The formulation for use in pain management according to claim 3, wherein the one or more secondary cannabinoids is present in an amount of up to 15% by weight of the primary cannabinoid.

### Claim 6 (depends on 1)

The formulation for use in pain management according to claim 1, wherein the formulation is prepared in a dosage form selected from the group consisting of a pill, tablet, gel capsule, syrup, oil-based spray, and liquid oil form.

### Claim 7 (depends on 1)

The formulation for use in pain management according to claim 1, wherein the formulation provides a total amount of from about 1 mg to about 25 mg of primary cannabinoid per dose.

### Claim 8 (depends on 7)

The formulation for use in a method of pain management according to claim 7, wherein the formulation provides a total amount of from about 5 mg to about 20 mg of primary cannabinoid per dose.

### Claim 9

A method for pain management in a subject in need thereof, comprising administering to said subject an effective amount of a formulation comprising a primary cannabinoid and one or more excipient, diluent or carrier;
wherein said primary cannabinoid consists of cannabichromene (CBC), and wherein said formulation is essentially free of tetrahydrocannabinol (THC).

### Claim 10 (depends on 9)

The method according to claim 9, wherein the pain management comprises alleviating pain due to neuropathic pain, cancer, chemotherapy, inflammation, diabetes, diabetic neuropathy, post-shingles neuralgia, peripheral neuropathy, multiple sclerosis, injury, accident, surgery, or tissue damage.

### Claim 11 (depends on 9)

The method according to claim 9, wherein the formulation additionally comprises one or more secondary cannabinoids.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the one or more secondary cannabinoids comprises cannabidiol (CBD).

### Claim 13 (depends on 11)

The method according to claim 11, wherein the one or more secondary cannabinoids is present in the formulation in an amount of up to 15% by weight of the primary cannabinoid.

### Claim 14 (depends on 9)

The method according to claim 9, wherein the formulation is administered in a dosage form selected from the group consisting of a pill, tablet, gel capsule, syrup, oil-based spray, and liquid oil form.

### Claim 15 (depends on 9)

The method according to claim 9, wherein the formulation provides to the subject a total amount of from about 1 mg to about 25 mg of primary cannabinoid per dose.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the formulation provides to the subject a total amount of from about 5 mg to about 20 mg of primary cannabinoid per dose.
